A Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation (XenMatrix)
2013年1月14日 更新者:C. R. Bard
A Prospective, Multi-Center Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation
This will be an observational study designed to collect early, short- and long-term clinical outcomes of the XenMatrix™ Surgical Graft for complex ventral hernia repair.
Subjects will be expected to attend follow up visits at 1, 6, 12, 18 and 24 months following surgery.
研究概览
地位
终止
条件
研究类型
观察性的
注册 (实际的)
4
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70808
- Our Lady of the Lake Regional Medical Center
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
非概率样本
研究人群
Subjects who are diagnosed with a ventral or incisional hernia that require a component separation repair with the use of a biological graft.
描述
Inclusion Criteria:
- Be able to undergo study procedures.
- Have signed an Informed Consent form (ICF).
- Be diagnosed with a ventral or incisional hernia that cannot be closed primarily in the opinion of the investigator.
- Requires a component separation repair with the use of a biological graft.
Exclusion Criteria:
- Subject is participating in another device or drug study.
- Subject has a life expectancy less than 4 years at the time of enrollment.
- Any condition in the opinion of the investigator that would preclude the use of the XenMatrix™ Surgical Graft, or preclude the subject from completing the follow-up requirements.
- Any subject with a defect the surgeon feels he/she cannot fully close.
- Subjects with a BMI > 50.
- Subjects with connective tissue disorders.
- Subjects with a history of cirrhosis.
- Subjects with renal failure requiring dialysis.
- Subjects on or suspected to be placed on chemotherapy or systemic immunosuppressive medications during any part of the study.
- Transplant recipients.
- Subjects taking corticosteroids for >6 months (pre or post surgery).
- Any bowel leak or infection that would preclude the use of the XenMatrix™ Surgical Graft in the opinion of the investigator.
- The subject lives approximately 2 hours away from the study site and compliance with follow up requirements will be difficult in the opinion of the investigator.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
XenMatrix
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To estimate the hernia recurrence rate of complex ventral hernias post repair with the XenMatrix™ Surgical Graft utilizing the component separation technique with several different tissue plane placements of the graft for up to 24 months post surgery.
大体时间:2 Years
|
Any hernia which is identified or confirmed by the investigator in approximately the same position as the hernia repair during any follow up visit after a XenMatrix™ surgical graft has been placed will be considered a recurrent hernia.
|
2 Years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To assess perioperative, short-term and long-term complications in subjects with complex hernias repaired with XenMatrix™ Surgical Graft and component separation.
大体时间:2 Years
|
Procedural and device related AEs collected from surgery until 24 months post surgery.
|
2 Years
|
|
To assess the procedural time for XenMatrix™ Surgical Graft placement with component separation.
大体时间:Day 0
|
Procedure time will be defined as beginning when the investigator makes the initial skin incision and ending when the skin closure is completed (skin to skin).
|
Day 0
|
|
To assess changes in subject quality of life (QOL) post repair with a XenMatrix™ Surgical Graft with component separation.
大体时间:2 years
|
Changes in QOL will be assessed from baseline to 24 months utilizing the Short Form-36 (SF-36) version 2.
|
2 years
|
|
To assess clinical outcomes based on the tissue plane placement of the XenMatrix™ Surgical Graft.
大体时间:2 years
|
Subjects who have their grafts placed in different tissue planes will have their recurrence rate, complication type and frequency examined to determine if there are any gross differences.
|
2 years
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
调查人员
- 首席研究员:Karl LeBlanc, MD、Our Lady of the Lake Regional Medical Center
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2010年9月1日
初级完成 (实际的)
2011年6月1日
研究完成 (实际的)
2011年6月1日
研究注册日期
首次提交
2010年12月22日
首先提交符合 QC 标准的
2011年2月25日
首次发布 (估计)
2011年2月28日
研究记录更新
最后更新发布 (估计)
2013年1月15日
上次提交的符合 QC 标准的更新
2013年1月14日
最后验证
2013年1月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.